In his new role, Dr. Sulkowski will oversee activities related to clinical trials, focusing on commercial clinical trials. In addition, he will help develop an integrated approach to trial-related training, support and oversight. He will join the team of Gail Daumit, the new vice dean for clinical investigation, and with her will collaborate closely with Daniel Ford, director of the Institute for Clinical and Translational Research.
Dr. Sulkowski came to Baltimore as an infectious diseases fellow at The Johns Hopkins Hospital, and subsequently joined the faculty in the Department of Medicine. Over his tenure, Dr. Sulkowski has developed a reputation across the institution as an insightful clinician and researcher, a dedicated educator and mentor, and an energetic and thoughtful leader.
He is director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center, and is the associate dean for research in the Capital Region for the school of medicine. Over the past 18 months, Dr. Sulkowski has played a key role in managing our COVID-19 clinical research efforts. He will continue in these roles.
Dr. Sulkowski has focused his research on developing more effective ways to treat viral hepatitis, including in patients who are also infected with HIV. He is medical director of the Infectious Diseases Viral Hepatitis Center at the school of medicine. He has published more than 300 articles, reviews and book chapters, and has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C. He is the past chair of the Hepatitis Transformative Sciences Group of the National Institutes of Health-funded adult AIDS Clinical Trials Group. He is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. In addition, he serves as the American editor of the Journal of Viral Hepatitis and has served on the editorial board of Hepatology.